Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus penpulimab in second-line unresectable osteosarcoma or soft tissue sarcoma
ChiCTR2200062533Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and penpulimab in osteosarcoma (OS) and soft tissue sarcoma (STS), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Progression-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
surufatinibpenpulimab
03
Conditions
osteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2200062533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062533.